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ABSTRACT Transgenic mice were generated by using the
a-myosin heavy chain promoter coupled to the coding sequence
ofa constitutively active mutant a1B-adrenergic receptor (AR).
These transgenic animals demonstrated cardiac-specific ex-
pression of this al-AR with resultant activation of phospholi-
pase C as shown by increased myocardial diacyiglycerol con-
tent. A phenotype consistent with cardiac hypertrophy devel-
oped in adult transgenic mice with increased heart/body
weight ratios, myocyte cross-sectional areas, and ventricular
atrial natriuretic factor mRNA levels relative to nontransgenic
controls. These transgenic animals may provide insight into the
biochemical triggers that induce hypertrophy in cardiac disease
and serve as a convenient experimental model for studies of this
condition.
Virtually all forms ofcardiac disease manifest some degree of
myocardial hypertrophy, with hypertrophy representing the
initial step in many diseases that progress to ventricular
failure. Despite the importance ofthis response in myocardial
pathophysiology, the biochemical initiators of hypertrophy
remain poorly understood. Several studies have documented
that pressure overload hypertrophy in vivo is associated with
the induction ofnuclear transcription factors (c-myc, c-fos) as
is similarly observed with the activation of cellular prolifer-
ation (1, 2). In addition, a number of hormonal stimuli have
been shown to induce these nuclear transcription factors and
mediate morphologic changes in cultured cardiac myocytes
(3). These agents include al-adrenergic receptor (a,-AR)
agonists, angiotensin II, thrombin, and endothelin 1 (4-7), all
ofwhich mediate cellular responses through binding to mem-
brane receptors and activating the guanine nucleotide binding
protein, Gq. Since Gq in turn activates the effector enzyme,
phospholipase C, and ultimately protein kinase C, these
enzymes may be important biochemical initiators of the
hypertrophic response (8). Studies of myocardial hypertro-
phy performed on isolated myocytes in vitro, however, have
significant limitations and may not have direct applicability to
in vivo hypertrophy. First, cultured myocytes are frequently
neonatal cells, which can be more easily maintained in vitro
but which are not fully differentiated and therefore may
respond differently to hormonal stimuli relative to adult
ventricular myocytes in vivo. Second, the time course for the
hypertrophic response generated in vitro is much more rapid
relative to the more chronic response to pressure overload
seen in vivo. Finally, important coregulatory hormonal and
cellular factors, which may be present in vivo, are excluded
from studies performed on isolated myocytes in culture.
Unfortunately, in vivo studies of hypertrophy involving the
systemic administration of agents such as a1-AR agonists to
laboratory animals are confounded by concomitant periph-
eral vasoconstriction, which might itself induce pressure-
overload hypertrophy.
In the present study, the signaling pathways coupled to the
al-AR were chronically activated, specifically in cardiac
myocytes ofadult transgenic mice. In this manner, the ability
ofthese pathways to induce myocardial hypertrophy could be
assessed in vivo in the absence of peripheral vascular
changes. These signaling pathways were activated by ex-
pressing a constitutively active mutant a,-AR; myocardial-
specific expression of this receptor was achieved by using the
a-myosin heavy chain (a-MHC) promoter (9). We have
previously characterized this constitutively active mutant
alB-AR, which contains point mutations in the third cyto-
plasmic loop (Arg2m - Lys, Lys2" - His, and Ala2"
Leu); the properties ofthis receptor include increased agonist
affinity and receptor/Gq protein coupling even in the absence
of agonist (10). Such mutant receptors by virtue of their
ability to activate specific signal transduction pathways in an
agonist-independent manner (10, 11) are useful tools to define
the effects of these pathways in a particular target tissue. In
this study, myocardial hypertrophy induced by this consti-
tutively active mutant receptor was assessed and quantitated
by measurements of myocardial mass, myocyte cross-sec-
tional areas, and ventricular atrial natriuretic factor (ANF)
mRNA levels.
MATERIALS AND METHODS
Transgene Constructs. The coding sequence (2 kb) for the
constitutively active mutant alB-AR (CAMalB-AR) was li-
gated into a pGEM-9ZF vector previously modified to con-
tain the simian virus 40 (SV40) intron/polyadenylylation
signal (12). This vector was then digested with Sac I and Sal
I and ligated to a 5.5-kb Sac I/Sal I fragment generated from
clone 20 (the murine a-MHC promoter) (9). The resultant
recombinant plasmid, pGEM-MHC-CAMa1B-SV40, was di-
gested with Sfi I and Not I to generate a linearDNA fiagment
(Fig. 1A) consisting of the a-MHC promoter, the constitu-
tively active mutant a1B-AR coding sequence, and the SV40
intron/polyadenylylation signal; this fragment was then mi-
croinjected into the pronuclei of single cell fertilized mouse
embryos to generate transgenic mice (13).
Northern Analysis. Mice were screened for the presence of
the transgene with Southern blots performed on tail genomic
DNA. To evaluate cardiac-specific transgene expression,
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FIG. 1. (A) DNA construct used for generation of constitutively
active mutant (CAM)alB-AR transgenic mice. (B) Representative
Northern blot demonstrating cardiac-specific mRNA expression of
the transgene. Total RNA was extracted from lung (LU), heart (HE),
quadriceps skeletal muscle (QU), diaphragm (DI), kidney (KI), and
liver (LI) of a CAMaiB-AR transgenic mouse; 50 lAg was loaded in
each lane. The blot was probed with a radiolabeled DNA fragment
consisting of the SV40 intron sequence and exposed to x-ray film for
48 hr at -70'C.
Northern analysis was performed on RNAs from numerous
tissues. Total RNA was extracted by the RNazol (Tel-Test,
Friendswood, TX) method (14), fractionated on a 1% aga-
rose/formaldehyde gel, and transferred to a nitrocellulose
membrane as described (12). Blots were then hybridized in a
50% formamide solution overnight at 420C with a random-
primer 32P-labeled DNA probe consisting of the SV40 intron
sequence; this probe has been shown not to cross-react with
endogenous murine mRNAs (12). Blots were washed twice in
0.2x SSC at 650C for 30 min before exposure to x-ray film.
Arterial Blood Pressure. Mice were anesthetized with ke-
tamine (100 mg/kg) and xylazine (5 mg/kg) (i.p.). A PES0
flame-stretched, fluid-filled catheter was introduced through
a cervical incision into the carotid artery and attached to a
modified P50 Statham transducer. Systolic, diastolic, and
mean blood pressures were recorded.
Ligand Binding Assays. Membrane fractions were prepared
from hearts (12) and resuspended in binding buffer (150 mM
NaCl/50 mM Tris HCl, pH 7.4/5 mM EDTA). Binding assays
were performed on 10-50 ,g of membrane protein using satu-
rating amounts of 2-{3(4-hydroxy-3-[125I]iodophenyl)ethyl-
aminomethyl}tetralone (-'.250 pM), an al-AR-specific ligand;
nonspecific binding was determined in the presence of 50 HM
prazosin. Reactions were conducted in 250 A1 of binding buffer
at 250C for 1 hr and then terminated by suction through
glass-fiber filters; all assays were performed in duplicate, and
receptor number (fmol) was normalized to mg of membrane
protein (15).
Diacyiglycerol (DAG) Quantitation. Lipid fractions were ex-
tracted from 50 mg of homogenized myocardial tissue (16).
Aliquots of lipid and DAG standards were dried under nitrogen,
resuspended in detergent micelles, and then completely phos-
phorylated using Escherichia coli DAG kinase and [y32P]ATP
(17). 32P-labeled phosphatidic acid (phosphorylated DAG) was
isolated by silica gel thin-layer chromatography and quantitated
with aPhosphorImager (MolecularDynamics, Sunnyvale, CA).
DAG content was normalized to tissue phospholipid (18) and
the finalDAG concentration was expressed as pmol ofDAG per
nmol of lipid phosphate.
Heart/Body Weight Ratios. Ten-week-old transgenic mice
and their littermate nontransgenic controls were anesthetized
with lethal doses of Avertin (0.03 ml per g body weight of a
2.5% solution) given i.p. The mice were weighed, and then
their hearts were excised, blotted three times on filter paper,
and weighed. Heart/body weight ratios were calculated and
expressed as mg/g.
Ventricular Myocyte Cross-Sectional Areas. Ten-week-old
transgenic mice and their littermate nontransgenic controls
were anesthetized as described above; hearts were excised
and then fixed for 4 hr in a buffered 1% formaldehyde
solution. The hearts were cut in halfalong a midsagittal plane,
paraffin embedded, and sectioned. Sections were then la-
beled with a fluorescein-conjugated wheat germ agglutinin
(19). Photomicrographs were taken of the mid-right ventric-
ular free wall (RV) and mid-left ventricular free wall (LV);
cross-sectioned myocytes were traced with a digitizer and a
computer program used to determine cross-sectional areas.
From each heart, 100 LV and/or 100 RV cross-sectioned
myocytes were individually measured by a blinded investi-
gator and the mean area was determined; final cross-sectional
areas were expressed as the average of the means from
multiple hearts ± SD of the individual means.
Ventricular ANF mRNA. Ventricular tissue was separated
from the atria with a dissecting microscope. Total RNA was
extracted, fractionated on a 1% agarose formaldehyde gel,
and transferred to nitrocellulose as described above. Blots
were prehybridized in a 50% formamide solution for 4 hr at
420C and then hybridized overnight with a random primer,
radiolabeled ANF cDNA probe. Blots were washed three
times in 0.2x SSC at 650C for 30 min before exposure to x-ray
film. All blots were then stripped in water at 95-100oC for 15
min and reprobed with the rat glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) cDNA probe (Ambion, Austin,
TX). The ANF and GAPDH bands were quantitated with a
Phosphorlmager, and the ANF/GAPDH signal intensity
ratio was reported.
Statistical Analysis. Data are reported as means ± SEM,
and statistical differences were determined by Student's t test
comparing transgenic values to controls unless otherwise
stated; P values < 0.05 were considered significant.
RESULTS AND DISCUSSION
Three transgenic lines were established expressing the
CAMaiB-AR (CAM7, CAM21, and CAM56). Northern blot
analysis using a SV40 intron probe, specific for the transgene
message, was performed on RNAs from different tissues of
adult transgenic animals. This demonstrated a distinct signal
in mRNA from the heart (Fig. 1B) with no evidence of
expression in other tissues. This cardiac-specific expression
is consistent with the previously documented pattern of
transgene expression achieved with the murine a-MHC pro-
moter (9, 12). Prior to birth, this promoter does not induce
ventricular expression of the transgene (9, 12). This feature
of the promoter ensures that the transgene affects predomi-
nantly differentiated ventricular myocytes, which have lost
the ability to undergo cell division. Therefore, the effect of
transgene expression on the development of hypertrophy is
less likely to be confounded by hyperplasia, which might
have been induced if the transgene had been fully expressed
in the ventricle during fetal or neonatal development.
Quantitation of al-AR expression was performed on myo-
cardial membrane fractions using radioligand binding assays
(Fig. 2). Total a1-AR expression in the CAM lines was 3-fold
higher than in littermate controls; all three CAM lines had
similar levels of receptor expression (Fig. 2). Competition
binding assays performed on membranes from CAM hearts
demonstrated "'.10-fold higher affinity for the agonist norepi-
nephrine compared with control membranes (data not
shown); this higher affinity for agonist is a property of the
constitutively active mutant receptor, which has been shown
in vitro (10).
Endogenous myocardial al-ARs have been shown to cou-
ple to phospholipase C activation, resulting in increased
intracellular DAG (20). Experiments were therefore con-
ducted on two of the transgenic lines (CAM21 and CAM7) to
10110 Physiology: Milano et al.
Proc. Natl. Acad. Sci. USA 91 (1994) 10111
150
T
E ,100
C)l 0~
U0uiI
-i T- IN- (D
o % 2 L
:c
L)<:
z 0 C.)
0
0)
FIG. 2. 2-{3-(4-Hydroxy-3-[1251]iodophenyl)ethylaminomethyl}-
tetralone radioligand binding in control and CAM transgenic myo-
cardial membranes. Mean a,-AR densities (Bmax) are shown for
control hearts (n = 6) and transgenic CAM21 (n = 6), CAM7 (n = 6),
and CAM56 (n = 3) hearts.
determine whether DAG was increased in the transgenic
myocardium. DAG was quantitated in lipid fractions from
CAM21 and nontransgenic control myocardium and was
significantly increased (78%) in transgenic hearts (Fig. 3).
Comparable significant increases (74%) in DAG were also
noted in CAM7 hearts compared with controls (data not
shown).
To exclude changes in peripheral vascular tone in these
transgenic mice, arterial blood pressures were measured.
Comparing seven control to eight transgenic (CAM7,
CAM21) mice, arterial pressures were not significantly dif-
ferent: 104 ± 12 versus 110 ± 18 (systolic; mean ± SD), 73
+ 12 versus 75 ± 13 (diastolic), and 84 ± 11 versus 86 ± 14
(mean blood pressure), respectively. This suggests that sig-
nificant changes in peripheral vascular tone are not induced
in the transgenic animals; therefore, myocardial changes in
these transgenic animals can be attributed to myocardial
expression of the transgene rather than to changes in blood
pressure.
Increases in heart/body weight ratios accompany myocar-
dial hypertrophy. Heart/body weight ratios were, therefore,
determined on 10-week-old CAM21 transgenic mice and
compared to littermate control animals. A significant in-
crease in this ratio (20%) was noted in the transgenic line
relative to control (Fig. 4).
The hallmark of hypertrophy is increased myocyte cross-
sectional area. Wheat germ agglutinin labeling of the sarco-
lemma allows for precise delineation of individual myocyte
borders (19, 21). Furthermore, obliquely sectioned myo-
cytes, which can confound the assessment of cross-sectional
area, can be identified by blurring ofthe myocyte borders and
excluded from the study (21). While immersion fixation in
formalin and subsequent paraffin processing may alter myo-
cyte dimensions, specimens would be affected equally; there-
fore, the ratio of transgenic to control myocyte cross-
sectional areas is maintained. Myocytes from both the RV
and the LV of CAM21 hearts were used for determination of
myocyte cross-sectional areas. For both, statistically signif-
icant increases in cross-sectional areas relative to littermate
controls were identified (Fig. 5 and Table 1). In the RV,
myocyte cross-sectional areas were increased 62%, an in-
crease that was comparable to that reported in mice under-
going banding ofthe pulmonary artery in a well characterized
in vivo murine model ofRV hypertrophy (22). To confirm the
finding ofhypertrophy in another line, myocytes from the LV
of CAM7 hearts were also studied and a similar significant
increase in myocyte cross-sectional area (62%) was demon-
strated (Fig. 5 and Table 1).
On the molecular level, the hypertrophic phenotype results
from a pattern of specific gene activation. This includes
upregulation of a number of genes normally expressed only
in the fetal myocardium-e.g., the f-MHC gene and the ANF
gene. While induction of the ,B-MHC gene during hypertro-
phy appears to be predominantly a feature of the rodent
species, ANF gene activation during ventricular myocyte
hypertrophy appears to be a conserved feature present in all
species studied (23). To examine ANF gene activation in the
ventricular chamber of these transgenic mice, Northern blots
were generated with control and transgenic ventricularRNAs
and probed with the mouse ANF cDNA (Fig. 6). Control
lanes demonstrated very faint or undetectable ANF signals,
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FIG. 3. Mass measurement of DAG in the transgenic CAM21
myocardium relative to control myocardium. Representative data
are shown from two independent experiments performed on lipid
fractions from control hearts (n = 5) and CAM21 hearts (n = 5). *,
P < 0.05 (Student's t test) relative to control values.
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FIG. 4. Heart/body weight ratios for adult CAM21 transgenic
mice relative to their respective nontransgenic littermate controls. A
total of 16 mice were studied: CAM21 (n = 7) and controls (n = 9).
*, P < 0.05 (Student's t test) relative to controls.
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FIG. 5. Representative wheat germ agglutinin-labeled myocar-
dial sections: control (nontransgenic littermate) right ventricle (A)
versus transgenic CAM21 right ventricle (B); control left ventricle
(C) versus CAM21 left ventricle (D); control left ventricle (E) versus
CAM7 left ventricle (F). (Bar = 25 pm.)
consistent with the inactivation of this gene in normal adult
ventricular myocytes (Fig. 6). Similarly, ventricular RNA
from transgenic animals overexpressing ($2-ARs (12) showed
essentially no signal (Fig. 6), suggesting that the expression
of an exogenous gene alone or the generation of functional
changes (as are present in the P2-AR transgenic animals) are
insufficient to trigger ANF gene activation. Conversely,
moderate ANF signals were seen in all lanes corresponding
to the CAM transgenic RNAs (Fig. 6). In general, CAM7
displayed stronger ANF signals relative to CAM21 (Fig. 6).
Equivalent GAPDH signals ensured that unequal loading or
degradation did not account for the increased ANF signals
noted in the transgenic lanes. Phosphorlmager analysis ofthe
Northern blots allowed for quantitation of the signal inten-
sity. The ANF/GAPDH signal intensity ratio was increased
-4-fold for CAM7 hearts relative to controls, 3.9 ± 0.92
arbitrary units (n = 8) versus 1.18 ± 0.10 (n = 5), respectively
(P < 0.05).
Constitutively expressed contractile protein genes may
also undergo transcriptional upregulation during hypertro-
phy. Relative levels of myosin light chain 2 (MLC-2) mRNA
have been shown to increase with hormonally induced myo-
Table 1. Averages of mean cross-sectional areas from hearts of
CAM21 and CAM7 transgenic mice relative to their respective
nontransgenic littermate controls
Cross-sectional area
Control Transgenic P value
CAM21 RV 130 ± 16 210 ± 28 0.0002
(n =6) (n =5)
CAM21 LV 183 ± 27 242 ± 31 0.008
(n =6) (n =5)
CAM7 LV 169 + 39 272 ± 71 0.022
(n =5) (n =5)
For each heart mean cross-sectional area was determined from 100
RV myocytes and/or 100 LV myocytes. Averages ± SD are given
with the P value for the Student t test comparing each transgenic
group to its respective control.
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FIG. 6. ANF mRNA levels in transgenic and control ventricular
myocardium. Two representative Northern blots are shown; each
was hybridized with a mouse ANFcDNA probe and exposed to x-ray
film for -18 hr at -70°C; each lane represents a different animal and
was loaded with 8 jg of total ventricular RNA from either CAM
transgenic animals (CAM7 and CAM21) or controls (C). Ventricular
RNA from two transgenic animals overexpressing the P2-AR was
included as an additional control on the upper blot (A2-WT, TG4).
Both blots were stripped and reprobed with a rat GAPDH cDNA
probe. Arrows indicate relative location of the 18S ribosomal band.
cyte hypertrophy in vitro (24). Northern blots with totalRNA
from transgenic and control ventricular tissue were probed
with a MLC-2 cDNA probe (data not shown). Comparing the
CAM transgenic animals to controls did not reveal significant
changes in MLC-2 signals. This finding parallels that reported
for a murine model of RV hypertrophy in which MLC-2
mRNA levels were equivalent between pulmonary artery-
banded animals and control animals (22). Unlike ANFmRNA
levels, MLC-2 mRNA levels are very high under normal
conditions and further increases may, therefore, be difficult
to identify. Alternatively, relative increases in MLC-2
mRNA may be a unique feature of myocyte hypertrophy in
vitro, which may not be present with hypertrophy in vivo.
Transgenic mice expressing the c-myc protooncogene or
SV40 T antigen in the myocardium develop marked increases
in cardiac growth (25, 26). While these important studies
emphasize the critical role of nuclear transcriptional activa-
tion on cardiac growth, they do not identify potential early
mediators that trigger myocardial transcriptional activation.
Furthermore, the predominant change noted in these studies
is hyperplasia, which is not typically part of the adult
myocardial response to pressure overload. In contrast, the
morphologic changes that develop in the transgenic mice
reported in this study provide important insight into the
potential early signals triggering changes in cardiac growth.
al-AR activation represents an early biochemical signal,
which through a complex cascade triggers nuclear transcrip-
tion. Furthermore, myocyte hypertrophy, the predominant
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phenotype noted in these animals, corresponds to the in vivo
response to pressure overload and other cardiac diseases.
The hypertrophy described in these transgenic mice qual-
itatively parallels that reported after microsurgical banding of
the pulmonary artery or aorta in mice (22, 27). However, the
relative increase in myocardial mass in these transgenic mice
is less impressive compared to that seen after banding. This
observation raises several important considerations. First,
the levels of expression of the constitutively active mutant
al-AR achieved in these transgenic mice may not completely
activate the associated second messenger systems; higher
levels of receptor expression may have induced a more
profound phenotype. Second, pressure-overload hypertro-
phy in vivo may result from the activation of multiple
biochemical pathways with a requirement for critical inter-
actions between these pathways; this would parallel the
events seen with the induction of cellular proliferation or
malignant transformation. Other important biochemical path-
ways that have been demonstrated to effect hypertrophy
include ras activation and calmodulin overexpression (28,
29). Viewed from this perspective, the capability of a single
gene or a single pathway to induce cardiac hypertrophy in
vivo is remarkable. Future experiments aimed at coactivating
different biochemical pathways (e.g., the a1-AR/phospholi-
pase C/protein kinase C system and the ras system) either in
cultured myocytes or in vivo using transgenic animals would
provide important insights into the key mediators of the
hypertrophic phenotype.
The increases in ventricular myocyte cross-sectional area
and in ANF mRNA induced in these transgenic animals
parallel changes that are seen in in vitro myocyte systems
after stimulation of Gq-coupled receptors (4-7). Therefore,
this transgenic phenotype validates in vitro myocyte systems
as models to study cardiac hypertrophy. Furthermore, these
results support the theory that myocardial Gq-coupled recep-
tors may actually mediate the myocardial hypertrophy asso-
ciated with cardiac disease.
Summary. This study demonstrates that expression of an
exogenous al-AR gene can be targeted specifically to the
myocardium of transgenic animals. Expression of this con-
stitutively active mutant a1B-AR resulted in activation of
phospholipase C, demonstrated by increased myocardial
DAG. A hypertrophic phenotype was induced with increased
heart/body weight ratios, increased myocyte cross-sectional
areas, and increased ventricular ANF mRNA levels. These
results demonstrate in vivo that activation of biochemical
pathways coupled to the al-AR is sufficient to induce the
hypertrophic phenotype, providing insight into the potential
biochemical triggers of this pathologic response.
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